Compare Equinix Inc (EQIX) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinix Inc vs Sanofi SA — how do they compare? Equinix Inc trades at $1,068.99 (market cap $105.50B), while Sanofi SA trades at $43.54 (market cap $104.30B). The key difference: Equinix Inc and Sanofi SA are close in size by market cap, and Sanofi SA pays the higher dividend (5.53%). Which is the better fit depends on your goals.
| EQIX | SNY | |
|---|---|---|
Market Cap | $105.50B | $104.30B |
Sector | Real Estate | Health |
52-Week High | $1.12K | $52.34 |
52-Week Low | $726.09 | $41.33 |
Enterprise Value | $126.63B | $124.19B |
Dividend Yield | 1.93% | 5.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinix (EQIX) trades at $1,069.17, up 2.47% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 EPS of $4.83, beating estimates, and raised its long-term growth outlook amid strong AI infrastructure demand. Revenue grew to $9.22 billion in 2025, with net income margin improving to 15.63%. However, valuation multiples like P/E of 66.44 and EV/EBITDA of 27.58 are elevated, and net cash flow turned negative in 2025 due to heavy investing activities.
The outlook is supported by robust analyst sentiment with a $1,120 consensus price target and 74.51% buy ratings, but risks include high leverage with debt-to-asset ratio rising to 47.13% in 2025 and earnings misses in two of the last three quarters. Investors should weigh growth potential against valuation and execution risks.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
